The present application describes uses for and articles of manufacture including Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population

The present invention relates to a method for treating triple-negative metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises nonpegylated liposomal doxorubicin, a taxane and a chemotherapeutic agent selected from the group consisting of capecitabine, vinorelbine, gemcitahine, carboplatin, and ixahepilone, and wherein said individual previously has been administered an anthracycline. In some embodiments, the individual...

Disclosed are vinorelbine derivatives represented by formula (I), or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising a therapeutically effective amount of vinorelbine derivatives or pharmaceutically acceptable salts thereof. Also disclosed are preparation method of vinorelbine derivatives or pharmaceutically acceptable salts thereof, and application in the preparation of medicaments for treating tumors. The vinorelbine derivatives show inhibiting activities...

A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.

A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens kits and methods for treatment of neoplasm including breast cancer including metastatic breast cancer and lung cancer using this combination optionally in combination with other anti-neoplastic agents or immune modulators are also described.

FIELD: medicine pharmaceutics.SUBSTANCE: group of inventions refers to medicine and aims at treating new growths. What is used is an effective amount of a first compound specified in (E)-N-{4-[3-chlor-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide an ester thereof an ether thereof carbamate or a pharmaceutically acceptable salt thereof and a second compound specified in vinorelbine or a pharmaceutically acceptable salt thereof. There are also describ...